39086-68-5

Basic information

• Product Name: 1-(CHLOROACETYL)DECAHYDROQUINOLINE
• Synonyms: 1-(CHLOROACETYL)DECAHYDROQUINOLINE;2-Chloro-1-(octahydro-quinolin-1(2H)-yl)ethanone;2-Chloro-1-(decahydroquinolin-1-yl)ethan-1-one
• CAS NO: 39086-68-5
• Molecular Formula: C₁₁H₁₈ClNO
• Molecular Weight: 215.72
• Mol File: 39086-68-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(CHLOROACETYL)DECAHYDROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(CHLOROACETYL)DECAHYDROQUINOLINE(39086-68-5)
• EPA Substance Registry System: 1-(CHLOROACETYL)DECAHYDROQUINOLINE(39086-68-5)

Safety Data

• Hazardous Substances Data: 39086-68-5(Hazardous Substances Data)

Usage

Chemical class

Quinoline derivative

Structural feature

Contains a chloroacetyl group as a substituent

Application

Pharmaceutical research

Use in research

Building block for the synthesis of biologically active compounds

Potential applications

Development of new drugs and medications

Structural properties

Contribute to its potential in drug development

Field of use

Organic chemistry

Role in organic chemistry

Reagent or intermediate in the synthesis of other organic compounds

Upstream product

• 79-04-9 chloroacetyl chloride 
• 1119900-30-9 trans-decahydroquinoline 
• 767-92-0 decahydroquinoline 

Relevant articles and documents

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 1: Identification and structure-activity relationships

Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)- ethanone 7b. Their related synthesis was also reported.